文献速递乳腺US乳腺X线

术前对比增强光谱乳腺摄影中额外病灶检出:二次超声与二次数字乳腺断层摄影的比较

Comparison between second-look ultrasound and second-look digital breast tomosynthesis in the detection of additional lesions with presurgical CESM.
PubMed 文献 · Br J Radiol · 2022-04-28

该研究回顾性纳入121例女性共128个术前对比增强光谱乳腺摄影(CESM)检出的额外病灶,比较二次超声与二次数字乳腺断层摄影(SL-DBT)单独及联合的检出效能。联合二次影像检出率75.8%,高于SL-DBT单独61.7%和二次超声单独55.5%;SL-DBT对非肿块强化和导管原位癌的检出率高于二次超声。

要点

  • CESM检出的额外病灶中,联合二次影像(SL-DBT+二次超声)检出率75.8%,高于任一单独方法。
  • SL-DBT对非肿块强化和导管原位癌的检出率高于二次超声,差异有统计学意义。
  • 联合二次影像检出91.2%最终病理为恶性的额外病灶,其余8.8%仍需MRI或MRI引导活检。

核心结论

  • 对于CESM检出的额外病灶,联合二次影像(SL-DBT+二次超声)的检出效能优于SL-DBT单独和二次超声单独。
  • 在B3病变、非肿块强化和焦点样病灶中,需更大样本分析以确定在SL-DBT基础上加做二次超声是否必要。

研究设计与样本

  • 回顾性研究,纳入2016年9月至2018年12月在本中心因术前分期接受CESM的121例女性,共128个额外病灶。
  • 所有额外病灶均行二次超声检查,并对CESM前1–3周进行的DBT进行回顾性判读作为SL-DBT。
  • 以活检后组织学、手术后标本或>24个月阴性随访为金标准,采用McNemar检验进行统计分析。

关键影像表现/征象

  • CESM图像上的额外病灶按强化类型(焦点、肿块或非肿块)、大小(<10 mm或>10 mm)和可疑程度(BI-RADS 2、3、4或5)评估。
  • 128个额外病灶中,二次超声发现影像学对应病灶71个(55.5%),SL-DBT发现79个(61.7%),两者联合发现53个(41.4%),两者任一发现97个(75.8%)。

诊断标准与关键数值

  • SL-DBT在非肿块强化模式的检出率高于二次超声(p=0.0325)。
  • SL-DBT在导管原位癌组织学类型的检出率高于二次超声(p=0.0081)。
  • 在总体样本中,加做SL-DBT较二次超声单独提高了检出效能(p<0.0001),且在所识别的每个亚组中均提高。
  • 在总体样本中,加做二次超声较SL-DBT单独提高了额外病灶检出率,且在每个亚组中均提高,但非肿块强化(p=0.0833)、焦点样病灶(p=0.0833)和B3病变(p=0.3173)除外。
  • 联合二次影像检出91.2%最终组织学证实为恶性的额外病灶,其余8.8%仍需MRI或MRI引导活检。

临床应用与阅片要点

  • CESM因高敏感度可用于术前分期,检测病变范围并识别常规影像未发现的额外病灶。
  • 由于CESM引导活检系统在临床实践中仍较少,需寻找其他方法对CESM检出的额外病灶进行组织学定性。
  • 联合二次影像(SL-DBT+二次超声)在额外病灶检出方面表现出优于SL-DBT单独或二次超声单独的性能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare second-look ultrasound (SL-ultrasound) with second-look digital breast tomosynthesis (SL-DBT) in the detection of additional lesions (ALs) with presurgical contrast-enhanced spectral mammography (CESM).

METHODS: We retrospectively included 121 women with 128 ALs from patients who underwent CESM for presurgical staging at our centre from September 2016 to December 2018. These ALs underwent SL-ultrasound and a retrospective review of DBT (SL-DBT) performed 1-3 weeks prior to CESM to evaluate the performance of each technique individually and in combination. ALs in CESM images were evaluated according to enhancement type (focus, mass, or non-mass), size (<10 mm or >10 mm) and level of suspicion (BI-RADS 2, 3, 4 or 5). Our gold-standard was post-biopsy histology, post-surgical specimen or >24 month negative follow-up. McNemar's test was used for the statistical analysis.

RESULTS: Out of the 128 ALs, an imaging correlate was found for 71 (55.5 %) with ultrasound, 79 (61.7%) with DBT, 53 (41.4 %) with DBT and ultrasound, and 97 (75.8%) with ultrasound and/or DBT. SL-DBT demonstrated a higher detection rate vs SL-ultrasound in non-mass enhancement (NME) pattern (p: 0.0325) and ductal carcinoma in situ histological type (p: 0.0081). Adding SL-DBT improved the performance vs SL-ultrasound alone in the overall sample (p: <0.0001) and in every subcategory identified; adding SL-ultrasound to SL-DBT improved the detectability of ALs in the overall sample and in every category except for NME (p: 0.0833), foci (p: 0.0833) and B3 lesions (p: 0.3173).

CONCLUSION: Combined second-look imaging (SL-DBT+ SL-ultrasound) for CESM ALs is superior to SL-DBT alone and SL-ultrasound alone. In B3 lesions, NME, and foci, the analysis of a larger sample could determine whether adding SL-ultrasound to SL-DBT is necessary or not.

ADVANCES IN KNOWLEDGE: Thanks to its high sensitivity, CESM is a useful tool in presurgical staging to detect the extent of the disease burden and identify ALs not detected with conventional imaging. Since CESM-guided biopsy systems are still scarcely available in clinical practice, it is necessary to look for other approaches to histologically characterize ALs detected with CESM. In our study, combined second-look imaging (SL-DBT + SL-ultrasound) showed better performance in terms of detectability of ALs, than either SL-DBT or SL-ultrasound alone, and allowed us to identify 91.2% of ALs that turned out to be malignant at final histology; for the remaining 8.8% it was still necessary to perform MRI or MRI-guided biopsy. However, this issue could be solved once CESM-guided biopsies spread in clinical practice. SL-DBT demonstrated a higher detection rate than SL-ultrasound in NME and ductal carcinoma in situ histology.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Bellini, Bicchierai, Amato, et al. Comparison between second-look ultrasound and second-look digital breast tomosynthesis in the detection of additional lesions with presurgical CESM. Br J Radiol. 2022. PMID: 35451312. doi:10.1259/bjr.20210927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。